ADL Amdl,

TUSTIN, Calif., June 18 /PRNewswire-FirstCall/ -- AMDL, INC. (AMEX:ADL), developer and marketer of cancer detection and vaccine technologies and with China-based pharmaceutical manufacturing, consumer sales and clinical trial activities, announced today a 1st Quarter Update Report on AMDL has been posted by Lauren Rudd (http://www.ruddreport.com/) with an 18 month target price of $22.00 and a Buy Recommendation. The twelve page report goes into significant detail about AMDL's products, technologies, its balance sheet, and its wholly owned subsidiary, Jade Pharmaceutical Inc. in China. "Due to its vast population, a rapidly growing economy, its large research and development investments ... and other capabilities, the People's Republic of China is often considered to be an emerging superpower," Mr. Rudd writes. "With over 20 million people, Shanghai is one of the most affluent population bases within China today and gaining market share for Jade's products in this key China market is a cornerstone of AMDL's sales growth in China." Mr. Rudd says in the report that with AMDL's most recent round of funding now completed, we look for these additional funds to enable Jade to increase its new sales number by $12.8 million, thereby bringing Jade's net revenues for the year 2007 to $14.2 million or about double what Jade did in 2006. As Jade's new distribution agreements develop their full potential, Mr. Rudd believes that net sales will again double by the end of 2008, reaching a total of $28.4 million and opined that such level of sales by Jade should result in gross profits for AMDL of about $7.1 million in 2007 and about $14.2 million in 2008. Rudd Report Disclaimer: This disclaimer is an integral part of our service. Please read it before investing in any security on which we report. Opinions are solely those of the staff of The Rudd Report and are subject to change without notice. Our reports are for information only and we do not offer securities or solicit the offer of securities of any company. Our reports are to inform the public and not to promote any company or its securities. We do not inform any company in advance of the nature or conclusions of our reports nor can a company change what we write. In the case of AMDL we received a fee for one-time first quarter coverage of the company in the amount of $3,000. Our reports contain factual statements and opinions. We derive these factual statements from sources that we believe are accurate. However, we do not represent that the facts presented are accurate or complete. Furthermore, the information contained in this report may become inaccurate because of the passage of time and should therefore be read for historical information only. About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com/. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460 DATASOURCE: AMDL, INC. CONTACT: Paul Knopick, +1-949-707-5365, voice mail, +1-714-505-4460, for AMDL, INC. Web site: http://www.amdl.com/ http://www.ruddreport.com/

Copyright